Analyst Ratings for [ILMN] Illumina, Inc.

3/4/25	Reiterated	Neutral	X
ILMN Illumina Citigroup
$130 $90
2/28/25	Downgrades	Buy Hold	X
ILMN Illumina HSBC Securities
$100
2/10/25	Downgrades	Eq Weight Underweight	X
ILMN Illumina Barclays
$130 $100
2/7/25	Downgrades	Buy Hold	X
ILMN Illumina TD Cowen
$177 $140
12/11/24	Downgrades	Buy Neutral	X
ILMN Illumina Citigroup
$190 $165
11/12/24	Resumed	Equal-Weight	X
ILMN Illumina Morgan Stanley
$156
10/17/24	Upgrades	Hold Buy	X
ILMN Illumina HSBC Securities
$180
8/28/24	Upgrades	Hold Buy	X
ILMN Illumina Argus
8/16/24	Upgrades	Neutral Buy	X
ILMN Illumina Daiwa Securities
$120 $154
8/14/24	Upgrades	Underweight Eq Weight	X
ILMN Illumina Barclays
$125
8/14/24	Upgrades	Hold Buy	X
ILMN Illumina TD Cowen
$126 $144
7/10/24	Upgrades	Neutral Buy	X
ILMN Illumina Citigroup
$140
6/3/24	Resumed	Hold	X
ILMN Illumina Jefferies
$115
1/16/24	Downgrades	Buy Hold	X
ILMN Illumina HSBC Securities
1/4/24	Downgrades	Outperform Mkt Perform	X
ILMN Illumina TD Cowen
$144
12/18/23	Upgrades	Sec Perform Sec Outperform	X
ILMN Illumina Scotiabank
$185
12/15/23	Upgrades	Underperform Mkt Perform	X
ILMN Illumina Bernstein
12/14/23	Initiated	Buy	X
ILMN Illumina Guggenheim
$155
12/14/23	Initiated	Overweight	X
ILMN Illumina Stephens
$170
12/13/23	Initiated	Outperform	X
ILMN Illumina Wolfe Research
$175
12/12/23	Downgrades	Neutral Underperform	X
ILMN Illumina BofA Securities
$140 $100
12/11/23	Upgrades	Sell Neutral	X
ILMN Illumina Citigroup
$85 $120
11/10/23	Downgrades	Buy Hold	X
ILMN Illumina Canaccord Genuity
$210 $120
9/28/23	Initiated	Underperform	X
ILMN Illumina Bernstein
$111
7/5/23	Resumed	Neutral	X
ILMN Illumina JP Morgan
$235
1/25/23	Downgrades	Buy Hold	X
ILMN Illumina Argus
1/5/23	Initiated	Sector Perform	X
ILMN Illumina Scotiabank
$216
12/12/22	Downgrades	Neutral Sell	X
ILMN Illumina Citigroup
$200 $180
12/7/22	Initiated	Outperform	X
ILMN Illumina RBC Capital Mkts
$282
10/4/22	Upgrades	Mkt Perform Outperform	X
ILMN Illumina SVB Leerink
$220 $270
9/28/22	Upgrades	In-line Outperform	X
ILMN Illumina Evercore ISI
$170 $250
8/25/22	Initiated	Neutral	X
ILMN Illumina Credit Suisse
$230
7/13/22	Downgrades	Eq Weight Underweight	X
ILMN Illumina Barclays
$350 $150
1/18/22	Upgrades	Hold Buy	X
ILMN Illumina Stifel
$480
1/11/22	Upgrades	Underweight Eq Weight	X
ILMN Illumina Barclays
1/7/22	Upgrades	Underperform Neutral	X
ILMN Illumina BofA Securities
1/6/22	Resumed	Equal-Weight	X
ILMN Illumina Morgan Stanley
$425
1/6/22	Resumed	Overweight	X
ILMN Illumina Piper Sandler
$450
10/15/21	Resumed	Outperform	X
ILMN Illumina Cowen
$550
6/1/21	Upgrades	Underperform In-line	X
ILMN Illumina Evercore ISI
$400
3/31/21	Downgrades	Overweight Neutral	X
ILMN Illumina Atlantic Equities
$390
3/31/21	Upgrades	Hold Buy	X
ILMN Illumina Canaccord Genuity
$445
3/3/21	Initiated	Underweight	X
ILMN Illumina Barclays
$325
12/22/20	Upgrades	Neutral Overweight	X
ILMN Illumina Piper Sandler
$340 $415
7/30/19	Downgrades	Buy Hold	X
ILMN Illumina Canaccord Genuity
$330 $300
7/12/19	Downgrades	Buy Underperform	X
ILMN Illumina BofA/Merrill
5/30/19	Initiated	Outperform	X
ILMN Illumina Wolfe Research
1/3/19	Upgrades	Neutral Buy	X
ILMN Illumina UBS
10/9/18	Initiated	Neutral	X
ILMN Illumina UBS
8/7/18	Upgrades	Underweight Eq-Weight	X
ILMN Illumina Morgan Stanley
7/31/18	Reiterated	Buy	X
ILMN Illumina Canaccord Genuity
$330 $340
2/5/18	Upgrades	Neutral Buy	X
ILMN Illumina Citigroup
1/31/18	Upgrades	Eq-Weight Overweight	X
ILMN Illumina First Analysis Sec
$277

ILMN Illumina, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.